Pharmanova Specialties Profile
Key Indicators
- Authorised Capital ₹ 5.75 Cr
as on 17-12-2024
- Paid Up Capital ₹ 5.18 Cr
as on 17-12-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 7.15 Cr
as on 17-12-2024
- Revenue -26.14%
(FY 2021)
- Profit -64.63%
(FY 2021)
- Ebitda -115.18%
(FY 2021)
- Net Worth -31.66%
(FY 2021)
- Total Assets 6.53%
(FY 2021)
About Pharmanova Specialties
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.75 Cr and a paid-up capital of Rs 5.18 Cr.
The company has closed loans amounting to ₹7.15 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Maneesh Sapte, Vinay Sapte, and Prasenjit Mukherjee serve as directors at the Company.
- CIN/LLPIN
U24233MH2014PTC252718
- Company No.
252718
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jan 2014
- Date of AGM
11 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pharmanova Specialties?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Maneesh Sapte  | Additional Director | 20-Aug-2019 | Current |
| Vinay Sapte | Additional Director | 20-Aug-2019 | Current |
| Prasenjit Mukherjee | Director | 24-Oct-2019 | Current |
Financial Performance and Corporate Structure Insights of Pharmanova Specialties.
Pharmanova Specialties Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 26.14% decrease. The company also saw a substantial fall in profitability, with a 64.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 31.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmanova Specialties?
In 2021, Pharmanova Specialties had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maneesh Pharmaceuticals LimitedActive 39 years 4 monthsManeesh Sapte and Vinay Sapte are mutual person
- Svizera Pharma Private LimitedActive 24 years 7 months
Maneesh Sapte and Vinay Sapte are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Jul 2015 | ₹7.15 Cr | Satisfied |
How Many Employees Work at Pharmanova Specialties?
Pharmanova Specialties has a workforce of 296 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmanova Specialties, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmanova Specialties's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
